Skip to main content
Sutra Platform

AI across the Life Sciences lifecycle — from compliance to clinic to commercial.

Sutra brings AI to Quality, Manufacturing, and Regulatory operations. The places where small mistakes become expensive ones — measured in months of delay, batches lost, and patients waiting.

The risks that build up quietly — before anyone sees them.

  • Compliance documentation that is too large and too scattered for anyone to navigate quickly. The answer is in there. The time to find it is not.
  • Batch deviations discovered after the damage is done and the batch is already gone.
  • Submissions filed with inconsistencies that only surface when the Complete Response Letter arrives.
  • Clinical enrollment delays that quietly compound for months before anyone has early warning.
  • Institutional knowledge that lives in a few experienced people's heads — and walks out the door when they leave.

Three products. One platform. The full development lifecycle covered.

Sutra agents watch your documentation, your manufacturing operations, and your regulatory lifecycle — surfacing risks, answering compliance questions on the spot, and giving your team the kind of visibility that used to live only in the experienced manager's head.

Stage 1
Early Stage
Sutra Intelligence
Stage 2
Clinical Stage
Sutra Regulatory
Stage 3
Commercial Stage
Sutra Manufacturing

Whether you are in early development or commercial manufacturing, Sutra brings the right capability to the stage that matters most right now.

What changes when Sutra is running.

Fewer findings on the next inspection

Contradictions, gaps, and documentation issues surface before an inspector raises them.

Recovered batch value

Deviations caught early. A single recovered batch is worth $170,000 to $220,000.

Lower submission risk

Cross-module gaps spotted before filing. Complete Response Letter risk measurably reduced.

Faster enrollment

Eligible patients identified at a scale manual chart review cannot match. Recruitment challenges account for 37% of clinical trial delays. (Tufts CSDD, 2024)